Cargando…

Modified Dose of Radioactive Iodine Therapy in a Patient With Thyroid Cancer on Peritoneal Dialysis: Case Report and Review of Literature

Thyroid malignancy is common among patients with renal impairment compared with the general population. Treatment involves surgical resection and radioactive iodine therapy (RAI) in high-risk patients. As a result of impaired iodine clearance in those with no residual kidney function, the determinat...

Descripción completa

Detalles Bibliográficos
Autores principales: Makeen, Ahmad, Alzahrani, Rawan, Dahlan, Sarah, Alwithenani, Raad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10556541/
https://www.ncbi.nlm.nih.gov/pubmed/37809149
http://dx.doi.org/10.7759/cureus.44754
_version_ 1785116895456788480
author Makeen, Ahmad
Alzahrani, Rawan
Dahlan, Sarah
Alwithenani, Raad
author_facet Makeen, Ahmad
Alzahrani, Rawan
Dahlan, Sarah
Alwithenani, Raad
author_sort Makeen, Ahmad
collection PubMed
description Thyroid malignancy is common among patients with renal impairment compared with the general population. Treatment involves surgical resection and radioactive iodine therapy (RAI) in high-risk patients. As a result of impaired iodine clearance in those with no residual kidney function, the determination of appropriate iodine dose is challenging. Evidence is lacking, and all previous reports are based on case studies with no universally accepted protocol.  We describe the case of a 30-year-old woman with end-stage renal disease on peritoneal dialysis (PD) who was diagnosed with papillary thyroid cancer while undergoing a pre-kidney transplant workup. She had a total thyroidectomy with modified radical neck dissection followed by a reduced-dose radioactive iodine therapy of 30 mCi based on her residual kidney function. Her PD prescription was adjusted to achieve a 2 L ultrafiltration daily. One year follow-up confirmed no evidence of residual nor recurrent disease. High-risk patients with differentiated thyroid malignancy require adjuvant radioactive iodine therapy. The optimal dose of RAI in the end-stage renal disease population is controversial. There are no clear guidelines available for patients with end-stage kidney disease including patients on peritoneal dialysis. Reduced dose therapy is probably effective in achieving the goals of therapy, with lower toxic risk to internal organs. Determining the appropriate schedule of each dialysis session in relation to RAI, the specific replacement prescription, and establishing a safe environment for medical staff dealing with such patients is important to consider. This article aims to highlight the need to establish a standardized protocol among patients with reduced kidney function treated with iodine therapy.
format Online
Article
Text
id pubmed-10556541
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-105565412023-10-07 Modified Dose of Radioactive Iodine Therapy in a Patient With Thyroid Cancer on Peritoneal Dialysis: Case Report and Review of Literature Makeen, Ahmad Alzahrani, Rawan Dahlan, Sarah Alwithenani, Raad Cureus Endocrinology/Diabetes/Metabolism Thyroid malignancy is common among patients with renal impairment compared with the general population. Treatment involves surgical resection and radioactive iodine therapy (RAI) in high-risk patients. As a result of impaired iodine clearance in those with no residual kidney function, the determination of appropriate iodine dose is challenging. Evidence is lacking, and all previous reports are based on case studies with no universally accepted protocol.  We describe the case of a 30-year-old woman with end-stage renal disease on peritoneal dialysis (PD) who was diagnosed with papillary thyroid cancer while undergoing a pre-kidney transplant workup. She had a total thyroidectomy with modified radical neck dissection followed by a reduced-dose radioactive iodine therapy of 30 mCi based on her residual kidney function. Her PD prescription was adjusted to achieve a 2 L ultrafiltration daily. One year follow-up confirmed no evidence of residual nor recurrent disease. High-risk patients with differentiated thyroid malignancy require adjuvant radioactive iodine therapy. The optimal dose of RAI in the end-stage renal disease population is controversial. There are no clear guidelines available for patients with end-stage kidney disease including patients on peritoneal dialysis. Reduced dose therapy is probably effective in achieving the goals of therapy, with lower toxic risk to internal organs. Determining the appropriate schedule of each dialysis session in relation to RAI, the specific replacement prescription, and establishing a safe environment for medical staff dealing with such patients is important to consider. This article aims to highlight the need to establish a standardized protocol among patients with reduced kidney function treated with iodine therapy. Cureus 2023-09-05 /pmc/articles/PMC10556541/ /pubmed/37809149 http://dx.doi.org/10.7759/cureus.44754 Text en Copyright © 2023, Makeen et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Endocrinology/Diabetes/Metabolism
Makeen, Ahmad
Alzahrani, Rawan
Dahlan, Sarah
Alwithenani, Raad
Modified Dose of Radioactive Iodine Therapy in a Patient With Thyroid Cancer on Peritoneal Dialysis: Case Report and Review of Literature
title Modified Dose of Radioactive Iodine Therapy in a Patient With Thyroid Cancer on Peritoneal Dialysis: Case Report and Review of Literature
title_full Modified Dose of Radioactive Iodine Therapy in a Patient With Thyroid Cancer on Peritoneal Dialysis: Case Report and Review of Literature
title_fullStr Modified Dose of Radioactive Iodine Therapy in a Patient With Thyroid Cancer on Peritoneal Dialysis: Case Report and Review of Literature
title_full_unstemmed Modified Dose of Radioactive Iodine Therapy in a Patient With Thyroid Cancer on Peritoneal Dialysis: Case Report and Review of Literature
title_short Modified Dose of Radioactive Iodine Therapy in a Patient With Thyroid Cancer on Peritoneal Dialysis: Case Report and Review of Literature
title_sort modified dose of radioactive iodine therapy in a patient with thyroid cancer on peritoneal dialysis: case report and review of literature
topic Endocrinology/Diabetes/Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10556541/
https://www.ncbi.nlm.nih.gov/pubmed/37809149
http://dx.doi.org/10.7759/cureus.44754
work_keys_str_mv AT makeenahmad modifieddoseofradioactiveiodinetherapyinapatientwiththyroidcanceronperitonealdialysiscasereportandreviewofliterature
AT alzahranirawan modifieddoseofradioactiveiodinetherapyinapatientwiththyroidcanceronperitonealdialysiscasereportandreviewofliterature
AT dahlansarah modifieddoseofradioactiveiodinetherapyinapatientwiththyroidcanceronperitonealdialysiscasereportandreviewofliterature
AT alwithenaniraad modifieddoseofradioactiveiodinetherapyinapatientwiththyroidcanceronperitonealdialysiscasereportandreviewofliterature